G1 Therapeutics to Present Data on Trilaciclib at North America Conference on Lung Cancer (NACLC)
RESEARCH TRIANGLE PARK, N.C., Oct. 15, 2020 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today announced that four presentations highlighting the myelopreservation benefits of trilaciclib and its ability to reduce the need for reactive interventions will be featured at the North America Conference on Lung Cancer (NACLC) being held October 16-17. Trilaciclib is a first-in-class investigational therapy designed to improve outcomes for people with cancer treated with chemotherapy.
G1 abstract titles are below; more details are available on the International Association for the Study of Lung Cancer (IASLC) website.
Title: Trilaciclib reduces the need for growth factors and red blood cell transfusions to manage chemotherapy-induced myelosuppression
Title: Trilaciclib has myelopreservation benefits in patients with small cell lung cancer treated with chemotherapy, irrespective of age
Title: Using an exploratory composite endpoint to evaluate the myelopreservation benefits of trilaciclib in patients with small cell lung cancer
Title: Myelopreservation with trilaciclib regardless of risk of chemotherapy-induced febrile neutropenia and/or anemia/red blood cell transfusions
About G1 Therapeutics
Occupant Wellness in the Indoor Environment
ROI Use Case